Literature DB >> 17121634

Pyrosequencing for rapid identification of carbapenem-hydrolysing OXA-type beta-lactamases in Acinetobacter baumannii.

T Naas1, L Poirel, P Nordmann.   

Abstract

Carbapenem-resistant Acinetobacter baumannii isolates producing carbapenem-hydrolysing oxacillinases are emerging worldwide. These enzymes are divided into four phylogenetic subgroups: OXA-23-like, OXA-51-like, OXA-24-like and OXA-58-like. A PCR-based approach linked to pyrosequencing analysis was developed to identify the genes for these beta-lactamases. Carbapenem-hydrolysing oxacillinases were rapidly and unambiguously identified in a collection of carbapenem-resistant clinical isolates of A. baumannii and Acinetobacter junii. Pyrosequencing may provide a rapid tool for identification of OXA variants, thus avoiding delays inherent in classical sequencing methods.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17121634     DOI: 10.1111/j.1469-0691.2006.01563.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  3 in total

1.  Typing of SHV extended-spectrum beta-lactamases by pyrosequencing in Klebsiella pneumoniae strains with chromosomal SHV beta-lactamase.

Authors:  Marjo Haanperä; Sofia D Forssten; Pentti Huovinen; Jari Jalava
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

2.  Rapid detection of aac(6')-Ib-cr quinolone resistance gene by pyrosequencing.

Authors:  Thomas Guillard; Véronique Duval; Hélène Moret; Lucien Brasme; Véronique Vernet-Garnier; Christophe de Champs
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

3.  Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.

Authors:  Koichi Tanimoto; Haruyoshi Tomita; Shuhei Fujimoto; Katsuko Okuzumi; Yasuyoshi Ike
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.